Copyright
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Pharmacol. Nov 28, 2022; 11(3): 27-47
Published online Nov 28, 2022. doi: 10.5497/wjp.v11.i3.27
Published online Nov 28, 2022. doi: 10.5497/wjp.v11.i3.27
Antidepressant-like potential of silymarin and silymarin-sertraline combination in mice: Highlighting effects on behaviour, oxidative stress, and neuroinflammation
Adejoke Yetunde Onaolapo, Department of Anatomy, Ladoke Akintola University of Technology, Oyo State 234, Nigeria
Hameed Sulaiman, Anthony Tope Olofinnade, Olakunle James Onaolapo, Department of Pharmacology, Ladoke Akintola University of Technology, Oyo State 234, Nigeria
Author contributions: Onaolapo AY and Onaolapo OJ conceived and designed the work that led to the submission; Sulaiman H and Olofinnade AT were responsible for the collection and collation of the data; Onaolapo AY and Onaolapo OJ were involved in the analysis of the data, interpretation of the results, and drafting of manuscript; all authors approved the final version of the manuscript.
Institutional animal care and use committee statement: All procedures were conducted in accordance with the approved protocols of the Ladoke Akintola University of Technology and within the provisions for animal care and use prescribed in the scientific procedures on living animals European Council Directive (EU2010/63).
Conflict-of-interest statement: All authors of this paper declare that there is no conflict of interest related to the content of this manuscript.
Data sharing statement: The data is presently unavailable in the public domain because the authors do not have permission to share data yet. Data would be made available only on request.
ARRIVE guidelines statement: The authors have read the ARRIVE guidelines, and the manuscript was prepared and revised according to the ARRIVE guidelines.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Olakunle James Onaolapo, MBBS, MSc, PhD, Reader (Associate Professor), Department of Pharmacology, Ladoke Akintola University of Technology, College of Health Sciences, P.M.B 4000, Ogbomosho 234, Oyo, Nigeria.
Received: April 18, 2022
Peer-review started: April 18, 2022
First decision: May 31, 2022
Revised: June 5, 2022
Accepted: October 19, 2022
Article in press: October 19, 2022
Published online: November 28, 2022
Processing time: 223 Days and 22.1 Hours
Peer-review started: April 18, 2022
First decision: May 31, 2022
Revised: June 5, 2022
Accepted: October 19, 2022
Article in press: October 19, 2022
Published online: November 28, 2022
Processing time: 223 Days and 22.1 Hours
ARTICLE HIGHLIGHTS
Research background
Depression is a neuropsychiatric disorder that has in recent times become a leading cause of disability and a major contributor to global disease burden and suicide.
Research motivation
There is increasing advocacy for the use of herbal supplements in depression management.
Research objectives
To determine the effect of silymarin dietary supplements alone or in combination with sertraline in a mouse model of depression.
Research methods
Preclinical study.
Research results
Silymarin mitigated dexamethasone-induced central nervous system changes in mice.
Research conclusions
Silymarin could have a place in the management of depression in humans.
Research perspectives
Further studies should be performed to examine the possible effects of silymarin in humans with depression.